T4K3.news
Health department ends mRNA vaccine contracts
US HHS terminates $500 million in mRNA vaccine funding, citing safety concerns.
The US HHS ends contracts worth $500 million amid questioning of mRNA vaccines.
Health department cuts mRNA vaccine funding amidst safety concerns
The US Department of Health and Human Services announced on Tuesday the termination of 22 federal contracts related to mRNA vaccines, casting doubt on the safety of this technology. This decision affects projects valued at nearly $500 million, which were integral during the Covid-19 pandemic. The Biomedical Advanced Research and Development Authority, which has been pivotal in developing vaccines, is halting its agreements, including one with Moderna concerning a bird flu vaccine. The HHS, under Secretary Robert F Kennedy Jr, who is known for his skepticism towards vaccines, cited a lack of effective protection from mRNA vaccines as a reason for the cuts. This move has followed a review initiated during the pandemic and comes alongside the dismissal of a panel of vaccine experts.
Key Takeaways
"We reviewed the science, listened to the experts, and acted."
Kennedy emphasizes the decision's basis on safety evaluations, although specifics are lacking.
"Data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu."
Kennedy's statement highlights his rationale for cutting funding while lacking cited evidence.
"This is a comprehensive review of mRNA-related investments initiated during the Covid-19 public health emergency."
HHS justifies the funding cuts as part of a systematic evaluation process.
The decision to end these contracts reflects a significant shift in US health policy, driven by Kennedy's long-held views on vaccines. By questioning the safety of mRNA technology, he steers public health towards alternative vaccines while fostering distrust in established practices. This move raises concerns about the scientific rigor of such decisions and the potential implications for public health initiatives. The abrupt changes could undermine confidence in vaccines, especially after they played a crucial role in combating Covid and saving lives. As Kennedy pursues a controversial agenda, the future of vaccine development in the US may face significant hurdles.
Highlights
- Health decisions based on safety concerns can reshape public trust.
- Terminating mRNA contracts challenges decades of vaccine progress.
- This shift in policy may deter scientific advancements in vaccinations.
- Stopping investment in mRNA technology could affect future health crises.
Policy changes raise concerns about vaccine safety and public health
The abrupt halt of mRNA funding under Kennedy's controversial leadership may result in public backlash and distrust in vaccines. This could hinder future vaccine development and public health initiatives, especially amid ongoing health threats.
The implications of this decision may extend far beyond funding stops, affecting public health perceptions.
Enjoyed this? Let your friends know!
Related News
Trump administration cuts mRNA vaccine funding
RFK Jr. ends $500 million funding for mRNA vaccines
Kennedy Cancels Major mRNA Vaccine Funding
Trump administration cancels mRNA vaccine funding
COVID-19 cases increase in California
Federal cuts impact bioscience research in Montana
RFK Jr cancels funding for mRNA vaccines
Kennedy cancels mRNA vaccine funding
